A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Latest Information Update: 17 Feb 2026
At a glance
- Drugs HMR-59 (Primary) ; Prednisone (Primary) ; Triamcinolone (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PARASOL
- Sponsors Janssen; Janssen Research & Development
Most Recent Events
- 13 Feb 2026 Planned End Date changed from 26 Feb 2026 to 18 Dec 2026.
- 15 Aug 2025 Planned End Date changed from 8 Mar 2026 to 26 Feb 2026.
- 15 Aug 2025 Planned primary completion date changed from 16 Jul 2025 to 26 Feb 2026.